Scholarlink

<p>Copper histidinate (ZYCUBO<sup>®</sup>) is a bioavailable copper replacement therapy developed by Cyprium Therapeutics and Sentynl Therapeutics for the treatment of Menkes disease, a genetic disorder caused by variants in the copper transporter gene, <i>ATP7A</i>. Because copper cannot be absorbed from the gastrointestinal tract by individuals with Menkes disease, copper histidinate is administered as a daily subcutaneous injection. In January 2026, copper histidinate received its first approval in the USA by the U.S. Food and Drug Administration for the treatment of Menkes disease in pediatric patients. Orphan Designation was granted by The European Commission to copper histidinate for the treatment of Menkes disease. This article summarizes the milestones in the development of copper histidinate leading to this first approval for Menkes disease in pediatric patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Copper Histidinate: Pediatric First Approval

  • 期刊论文

  • 发表日期：

    2026年4月22日

查看全文
  • Hannah A. Blair

摘要

Copper histidinate (ZYCUBO®) is a bioavailable copper replacement therapy developed by Cyprium Therapeutics and Sentynl Therapeutics for the treatment of Menkes disease, a genetic disorder caused by variants in the copper transporter gene, ATP7A. Because copper cannot be absorbed from the gastrointestinal tract by individuals with Menkes disease, copper histidinate is administered as a daily subcutaneous injection. In January 2026, copper histidinate received its first approval in the USA by the U.S. Food and Drug Administration for the treatment of Menkes disease in pediatric patients. Orphan Designation was granted by The European Commission to copper histidinate for the treatment of Menkes disease. This article summarizes the milestones in the development of copper histidinate leading to this first approval for Menkes disease in pediatric patients.